retatrutide update october 2025 is the most significant weight-loss pharmaceutical currently in clinical development., Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of Incretin triple agonist retatrutide (LY3437943)

It is studied in sleep physiology, stress response, neuroendocrine regulation, and antioxidant activity research

Results from the Phase III TRIUMPH-4 (NCT05869903) clinical trial released last month show retatrutide produced significant weight loss and improved pain and physical function among patients with obesity or overweight and knee osteoarthritis at 68 weeks

doi: 10.3390/jcm10153240

#weightloss #obesity #GLP1 #glucagon #clinicaltrial #drugdiscovery #biopharma #biotech The door was open- we walked past it

Already a subscriber

First, current research on ferroptosis has only touched on the phenomenon, and the detailed roles of ferroptosis in the onset and development of human diseases have not been deeply studied, posing a challenge for precision medicine